Search All Tech Briefings

Search technology briefings produced by NIHR Innovation Observatory. These are short reports on new or repurposed medicines that we have already sent to our stakeholders. Only those technologies (medicines) that are within the scope of our stakeholders will have a technology briefing available. Search our technology briefings by intervention (drug or device), specific indication (disease or condition), or general therapeutic area.

| 81 Results

Clear All Filters

Title	Intervention	Indication	Therapeutic Area	Year	Actions
Pembrolizumab with stereotactic body radiotherapy for unresected stage I or II non-small cell lung cancer	Pembrolizumab (Keytruda; MK-3475) , Stereotactic body radiotherapy	Non-small-cell lung cancer (NSCLC)	Lung and Respiratory Cancer	2022	View \| Download
Pembrolizumab-vibostolimab for previously untreated non-small-cell lung cancer (NSCLC)	Pembrolizumab-vibostolimab (MK-7684)	Non-small-cell lung cancer (NSCLC)	Lung and Respiratory Cancer	2023	View \| Download
Plinabulin in addition to docetaxel for advanced, metastatic non-small-cell lung cancer - second line or greater	Docetaxel (Taxotere; docetaxel trihydrate; docetaxel anhydrous) , Plinabulin (BPI-2358)	Non-small-cell lung cancer (NSCLC)	Lung and Respiratory Cancer	2020	View \| Download
Pralsetinib for RET-fusion positive metastatic non-small-cell lung cancer	Pralsetinib (BLU-667; Gavreto)	Non-small-cell lung cancer (NSCLC)	Lung and Respiratory Cancer	2020	View \| Download
Ramucirumab in addition to erlotinib for EGFR mutation-positive metastatic non-small-cell lung cancer	Erlotinib (Tarceva; erlotinib hydrochloride) , Ramucirumab (Cyramza)	Non-small-cell lung cancer (NSCLC)	Lung and Respiratory Cancer	2019	View \| Download
Repotrectinib for treating advanced or metastatic nonsmall-cell lung cancer with ROS1-postive mutation	Repotrectinib (TPX 0005)	Non-small-cell lung cancer (NSCLC)	Lung and Respiratory Cancer	2023	View \| Download
Sacituzumab govitecan for previously treated advanced non-small cell lung cancer	Sacituzumab Govitecan (IMMU-132; Trodelvy)	Non-small-cell lung cancer (NSCLC)	Lung and Respiratory Cancer	2023	View \| Download
Selpercatinib for metastatic RET fusion-positive non-small cell lung cancer	Selpercatinib (LOXO-292; LY3527723)	Non-small-cell lung cancer (NSCLC)	Lung and Respiratory Cancer	2019	View \| Download
Selpercatinib for previously untreated advanced RET fusion-positive non-small cell lung cancer	Selpercatinib (LOXO-292; LY3527723)	Non-small-cell lung cancer (NSCLC)	Lung and Respiratory Cancer	2021	View \| Download
Selpercatinib for treating advanced solid tumours with RET gene fusion in people aged 12 years and older	Selpercatinib (LOXO-292; LY3527723)	Non-small-cell lung cancer (NSCLC)	Lung and Respiratory Cancer	2023	View \| Download